Optimi Health Ships First MDMA Internationally to Israel, Gains CBSA Export Authorization

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN), a prominent Health Canada licensed GMP psychedelics pharmaceutical manufacturer specializing in controlled substances like botanical psilocybin and MDMA, has announced significant advancements in its international psychedelic supply operations and corporate marketing strategy.

Optimi has successfully completed its inaugural international shipment of MDMA active pharmaceutical ingredient (API) to the Institute for Psychedelic Research at Tel Aviv University (IPR-TLV) in Israel. This landmark achievement, facilitated by the issuance of the necessary Export Permit from Health Canada, represents a crucial step in Optimi’s mission to support global psychedelic research and push forward innovation in this field.

Bill Ciprick, CEO of Optimi, highlighted the importance of this milestone. "Completing our first international export of MDMA to Israel is a significant achievement for our company. Now that we possess our Drug Establishment Licence, this accomplishment underlines our ability to produce MDMA in-house for clients globally and to deliver the product efficiently to an international client. It also demonstrates our commitment to expanding the availability of high-quality, controlled substances for critical scientific research and therapeutic applications worldwide."

In addition to the export, Optimi has secured the CERS (Canadian Export Reporting System) and CBSA (Canada Border Services Agency) Exporters Authorization ID. This authorization is vital for adhering to international trade regulations and ensuring smooth logistics for future shipments to customers globally.

Moreover, Optimi announced its engagement with Oak Hill Financial Inc. to provide comprehensive investor relations, business, and capital markets advisory services. Oak Hill will assist Optimi in effectively communicating its latest corporate milestones to potential new investors and further engaging with the investment community on behalf of the company. This partnership is expected to bolster Optimi’s investor relations efforts, as noted by Jacob Safarik, Chief Financial Officer of Optimi. "Their expertise will be invaluable as we expand our shareholder base and reach new milestones in the psychedelic pharmaceuticals industry."

Recent corporate highlights include the awarding of a Drug Establishment Licence by Health Canada on June 3, 2024. This licence allows Optimi to produce and distribute MDMA and psilocybin capsules and fabricate Active Pharmaceutical Ingredients (APIs) extracted from plant sources. The recognition by Health Canada as a GMP-compliant pharmaceutical drug manufacturer marks a significant step for the company.

Additionally, Optimi’s MDMA and psilocybin capsules are now available for psychiatrists in Australia, who can request their importation for patients. The available drugs include MDMA Capsules (40mg and 60mg) for PTSD and Psilocybin Capsules (5mg) for Treatment-Resistant Depression. Optimi has also received an import certificate to supply an initial order of 160 doses of MDMA and psilocybin to meet patient prescriptions, facilitated by Mind Medicine Australia.

With its comprehensive GMP psychedelic drug solutions, Optimi can now provide customers with services covering manufacturing, export, and distribution from their Princeton, BC, Canada facility. This ensures that all products are grown and manufactured in-house under strict GACP and GMP conditions, guaranteeing unparalleled quality and reliability. Optimi Health remains committed to being the most trusted supplier of safe drug candidates worldwide.